Investigator Research Support Program
Request for Applications (RFA) — Cycle 1: 2026
Program Overview
- Proposals are welcome across all research stages with priority given to clinical stage studies.
- Sorridi will provide standardized NeuroFiber® formulations as study interventions and research support funding.
NeuroFiber® supports investigator-initiated science at the intersection of diet, the gut microbiome, and human health. We welcome proposals from all career stages.
Funding Amount & Key Dates
Funding
- Up to $15,000 per project
- 5 awards in 2026
- Additional support for presenting and publishing work is possible
Areas of Interest
Neurological Conditions
- Parkinson's disease and related synucleinopathies
- Alzheimer's disease and other dementias
- Multiple sclerosis
- Stroke and cerebrovascular disease
- Migraine and headache disorders
- Any condition with gut-brain axis involvement
Gastrointestinal Conditions
- Constipation and motility disorders
- Intestinal inflammation and permeability
- Irritable bowel syndrome
- Inflammatory bowel disease
- Gut microbiome dysbiosis in disease contexts
Eligibility
Clinical
Fellows, residents, and physicians at accredited medical institutions
Academic
Researchers at universities, research institutes, or medical centers
Early Career
Early career investigators are especially encouraged to apply
Applicants must have the institutional resources and oversight necessary to complete the proposed work, including applicable ethical approvals (IACUC, IRB, or equivalent) prior to project initiation.
Application Requirements
Applications should be concise and include:
Biosketch or CV
Investigator biosketch or full curriculum vitae
Project Summary
300 words or fewer describing the proposed work
Specific Aims & Plan
Brief research plan including proposed use of study material and expected outcomes
Timeline & Budget
Project timeline and budget narrative within the $15,000 limit
Review and Selection Process
Evaluation Criteria
Scientific merit, innovation, feasibility, and relevance to microbiome-diet-host interactions and patient care
Decision Process
Final funding decisions will be made by an internal review board
Notification
All applicants will be notified of decisions via email by the dates listed above
NeuroFiber®
About the Study Intervention
- Available as a prebiotic powder and whole-food bar, each containing a proprietary multi-fiber blend formulated to enrich SCFA-producing bacterial populations and support microbiome balance and function.
- Delivers a spectrum of bioactive compounds from whole-food sources including polyphenols, catechins, healthy fats, and essential vitamins.
- Contains clinically relevant combinations of resistant starches and prebiotic fibers designed to modulate the gut microbiome and related host pathways.
Research & Evidence
- Relevant publication: biorxiv.org — 10.64898/2026.04.13.718214
- A pilot clinical study in adults with Parkinson's disease has been completed. Manuscript in preparation for peer-reviewed publication.
- A preliminary report is available upon request at sorriditherapeutics.com/grants
Preliminary Clinical Report
A pilot clinical study in adults with Parkinson’s disease using NeuroFiber®. The manuscript is currently being prepared for peer-reviewed publication. This document is provided for reference only and is not for distribution.
Dissemination Support
Publication Support
We encourage the presentation and publication of all research conducted under this grant program.
Conference & Open Access
Additional support for conference registration, travel, and open-access publication fees is available upon request.
Terms and Conditions of Award
By accepting an award, investigators agree to the following:
Publication Rights
Awardees retain full rights to publish findings regardless of outcome, including negative or null results. Sorridi requests a 30-day review period prior to any submission and must be acknowledged in all publications.
Data Sharing
Awardees agree to share primary study data upon completion or publication, whichever comes first. Data used for internal scientific purposes only and not shared with third parties without consent.
Conflict of Interest
All publications and presentations must disclose receipt of product supply and research funding from Sorridi Therapeutics per journal and institutional conflict of interest policies.
Progress Reporting
A brief progress report at 6 months and a final report within 90 days of completion. Reports should summarize progress, key findings, and protocol modifications.